Takuya Koie

Gifu-shi, 5011194, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 311 publications

Recurrent Invasive Clear Cell Subtype of Upper Tract Urothelial Carcinoma Responding to Enfortumab Vedotin and Pembrolizumab After Chemotherapy: A Case Report.

Recurrent Invasive Clear Cell Subtype of Upper Tract Urothelial Carcinoma Responding to Enfortumab Vedotin and Pembrolizumab After Chemotherapy: A Case Report.

Journal: Archivos espanoles de urologia

Published: August 17, 2026

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.

Journal: The New England journal of medicine

Published: July 22, 2026

Reply to the Letter to the Editor Regarding "Age and Nocturnal Polyuria in Nocturia: A Multicenter Voiding Diary Cohort Study".

Reply to the Letter to the Editor Regarding "Age and Nocturnal Polyuria in Nocturia: A Multicenter Voiding Diary Cohort Study".

Journal: Neurourology and urodynamics

Published: June 20, 2026

Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status.

Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: June 15, 2026

Editorial Comment on Prevalence and Factors Associated With Nocturia (≥ 2 Night-Time Urinary Episodes) in Japan: Analysis of the 2023 Japan Community Health Survey (JaCS 2023).

Editorial Comment on Prevalence and Factors Associated With Nocturia (≥ 2 Night-Time Urinary Episodes) in Japan: Analysis of the 2023 Japan Community Health Survey (JaCS 2023).

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: June 10, 2026

Editorial Comment on Prognostic Value of Inflammatory Biomarkers as Continuous Variables in Metastatic Renal Cell Carcinoma: Linearity Assessment, Proportional Hazards Assumption Testing, and Time-Varying Effects.

Editorial Comment on Prognostic Value of Inflammatory Biomarkers as Continuous Variables in Metastatic Renal Cell Carcinoma: Linearity Assessment, Proportional Hazards Assumption Testing, and Time-Varying Effects.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: June 10, 2026

Regulation of TMEM2-mediated hyaluronan degradation by CD44 and LYVE-1.

Regulation of TMEM2-mediated hyaluronan degradation by CD44 and LYVE-1.

Journal: Frontiers in molecular biosciences

Published: April 10, 2026

Age and Nocturnal Polyuria in Nocturia: A Multicenter Voiding Diary Cohort Study.

Age and Nocturnal Polyuria in Nocturia: A Multicenter Voiding Diary Cohort Study.

Journal: Neurourology and urodynamics

Published: April 01, 2026

Incidence and Short- to Intermediate-Term Oncological Outcomes of Pathological T0 Prostate Cancer After Robot-Assisted Radical Prostatectomy: A Multicenter, Retrospective Cohort Study in Japan (MSUG94 Group).

Incidence and Short- to Intermediate-Term Oncological Outcomes of Pathological T0 Prostate Cancer After Robot-Assisted Radical Prostatectomy: A Multicenter, Retrospective Cohort Study in Japan (MSUG94 Group).

Journal: Current oncology (Toronto, Ont.)

Published: March 30, 2026

Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy.

Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy.

Journal: International journal of clinical oncology

Published: February 20, 2026

Real-World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study.

Real-World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: February 17, 2026

Editorial Comment on Bayesian Reinterpretation of the CheckMate-9ER Final Analysis: Organ-Site and IMDC Risk-Stratified Probabilities of Benefit.

Editorial Comment on Bayesian Reinterpretation of the CheckMate-9ER Final Analysis: Organ-Site and IMDC Risk-Stratified Probabilities of Benefit.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: February 10, 2026

Showing 1-12 of 311

Last Updated: 09/26/2026